Target 2035 - an update on private sector contributions.
Suzanne AcklooAlbert A AntolinJose Manuel BartolomeHartmut BeckAlex N BullockUlrich A K BetzJark BöttcherPeter J BrownMenorca ChaturvediAlisa CrispDanette L DanielsJan DreherKristina EdfeldtAled Morgan EdwardsUrsula EgnerJon ElkinsChristian FischerTine GlendorfSteven GoldbergIngo V HartungAlexander HillischEvert J HomanStefan KnappMarkus KösterOliver KrämerJosep LlaveriaUta LesselSven LindemannLars LinderothHisanori MatsuiMaurice MichelFlorian MontelAnke Mueller-FahrnowSusanne MüllerDafydd R OwenKumar Singh SaikatenduVijayaratnam SanthakumarWendy SandersonCora ScholtenMatthieu SchapiraSujata SharmaBrock ShiremanMichael SundströmMatthew H ToddClaudia TredupJennifer VenableTimothy M WillsonCheryl H ArrowsmithPublished in: RSC medicinal chemistry (2023)
Target 2035, an international federation of biomedical scientists from the public and private sectors, is leveraging 'open' principles to develop a pharmacological tool for every human protein. These tools are important reagents for scientists studying human health and disease and will facilitate the development of new medicines. It is therefore not surprising that pharmaceutical companies are joining Target 2035, contributing both knowledge and reagents to study novel proteins. Here, we present a brief progress update on Target 2035 and highlight some of industry's contributions.